tiprankstipranks
Halozyme Therapeutics Achieves Record Revenue in 2024
PremiumCompany AnnouncementsHalozyme Therapeutics Achieves Record Revenue in 2024
1M ago
Positive Outlook and Strategic Growth: Brendan Smith’s Buy Rating on Halozyme
Premium
Ratings
Positive Outlook and Strategic Growth: Brendan Smith’s Buy Rating on Halozyme
1M ago
Halozyme reports Q4 EPS $1.06, consensus $1.16
Premium
The Fly
Halozyme reports Q4 EPS $1.06, consensus $1.16
1M ago
Halozyme Board Member Connie Matsui Steps Down
PremiumCompany AnnouncementsHalozyme Board Member Connie Matsui Steps Down
1M ago
Halozyme’s Strategic Advancements and Market Potential Justify Buy Rating
Premium
Ratings
Halozyme’s Strategic Advancements and Market Potential Justify Buy Rating
2M ago
Positive Regulatory Developments and Revenue Growth Potential Support Buy Rating for Halozyme Therapeutics
Premium
Ratings
Positive Regulatory Developments and Revenue Growth Potential Support Buy Rating for Halozyme Therapeutics
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100